04.Issue 12 december 23 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 10, Issue : 12, December – 2023

Title:

REVIEW ON THE CURRENT CHALLENGES IN VACCINE DEVELOPMENT

Authors :

Prathmesh G. Pare, Dr. A. M. Wankhade

Abstract :

Global health has been greatly impacted by vaccines. Smallpox, rinderpest, and several other major infections have been eradicated. A variety of infectious diseases of childhood have been significantly improved by whom in the past decade. As polio has been virtually eradicated, and measles has been controlled successfully, it may also be eradicated soon. Vaccines can prevent infections such as pneumonia and diarrhoea which cause 6.6 million deaths each year. Due to new pneumococcal conjugate vaccines and rotavirus vaccines, childhood mortality is expected to decline further. As of now, malaria, tuberculosis, and HIV vaccines have had modest success. Vaccinations that stimulate different immune systems and it may be the most effective way to prevent these infections. Reverse and structural vaccinology have revealed novel antigen candidates and molecular immunology has led to the formulation of promising adjuvants. Gene expression profiles and immune parameters in patients, vaccinees and healthy controls have formed the basis for biosignatures that will provide guidelines for future vaccine design. On a long-term basis, vaccines may prevent or modulate diseases other than infectious diseases. It is already possible to develop cancer vaccines, and in the future it will be possible to develop vaccines for addictions, diabetes, hypertension, and Alzheimer’s disease as well.
KEYWORDS: Vaccine. Technology, Immunity, Challenges, Regulatory.

Cite This Article:

Please cite this article in press Prathmesh G. Pare et al, Review on The current challenges in vaccine development, Indo Am. J. P. Sci, 2023; 10 (12).

Number of Downloads : 10

References:

1. AUDIBERT, F., JOLIVET, M., CHEDID, L., ARNON, R. & SELA, M. (1982) Successful immunisation with a totally synthetic diphtheria vaccine. Proc. Natn. Acad. Sci. USA. 79, 5042.
2. BEALE, A.J. (1985) Perspective of a traditional manufacturer. In Modern Approaches to The Development of Vaccines (ed. by R. Chanock, R.A. Lerner & F. Brown) Cold Spring Harbor Laboratories, New York, USA. In press.
3. FORMAL, S.B., BARON, L.S., KOPECKO, D.J., WASHINGTON, O., POWELL, C.
& LIFE, C.A. (1981) Construction of a potential bivalent vaccine strain: introduction of shigella sonnei form 1 antigen genes into gal E salmonella typhi Ty2Ia typhoid vaccine strain. Infect. Immun. 34, 746
4. HOISETH, S.K. & STOCKER, B.A.D. (1981) Aromatic dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature, 291, 238. HOWARD, J.G., NICKLIN, S., HALE, C. & LIEW, F.Y.
5. SELA, M. & ARNON, R. (1984) Synthetic antigens and vaccines. Interdisciplinary Sci. Rev. 9, 271.
6. Dannenberg, A. M., Jr (2010). Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin Microbiol Rev 23, 781–794
7. Ebensen, T. & Guzma´n, C. A. (2009). Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design. Adv Exp Med Biol 655, 171– 188
8. Ferreira, D. M., Jambo, K. C. & Gordon, S. B. (2011). Experimental human pneumococcal carriage models for vaccine research. Trends Microbiol 19, 464–470.
9. Kaufman, D. R., De Calisto, J., Simmons, N. L., Cruz, A. N., Villablanca, E. J., Mora, J. R. & Barouch, D. H. (2011). Vitamin A deficiency impairs vaccine-elicited gastrointestinal immunity. J Immunol 187, 1877–1883.
10. Marzetta, C. A., Lee, S. S., Wrobel, S. J., Singh, K. J., Russell, N. & Esparza, J. (2010). The potential global market size and public health value of an HIV-1 vaccine in a complex global market. Vaccine 28, 4786–4797.
11. Minassian, A. M., Ronan, E. O., Poyntz, H., Hill, A. V. & McShane, H. (2011). Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy. PLoS ONE 6, e19840.
12. Outterson, K. & Kesselheim, A. S. (2008). Market-based licensing for HPV vaccines in developing countries. Health Aff (Millwood) 27, 130–139.
13. Sette, A. & Rappuoli, R. (2010). Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33, 530–541.
14. Sette, A. & Rappuoli, R. (2010). Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33, 530–541.
15. Maslow JN. Vaccine development for emerging infectious diseases. Vaccine. 2017;35:5437–43. doi:10.1016/j.vaccine.2017.02.015.
16. Roberts CC. Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development. Hum Vaccin Immunother. 2019;15:2258–2263. doi:10.1080/ 21645515.2019.1634992.
17. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327–40. doi:10.1056/ NEJMoa1800820.
18. Galula JU, Salem GM, Chang GJ, Chao DY. Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era? Hum Vaccin Immunother. 2019;15:2328– 2336. doi:10.1080/21645515.2019.1643676.
19. Kasabi GS, Murhekar MV, Sandhya VK, Raghunandan R, Kiran SK, Channabasappa GH, Mehendale SM, Bausch DG. Coverage and effectiveness of Kyasanur forest disease (KFD) vaccine in Karnataka, South India, 2005-10. PLoS Negl Trop Dis. 2013;7(1):e2025. doi:10.1371/journal.pntd.0002025.
20. Reyes-Sandoval A. 51 years in of chikungunya clinical vaccine development: a historical perspective. Hum Vaccin Immunother. 2019;15:2351–2358. doi:10.1080/21645515.2019.1574149.
21. Nadeem MS, Ali A, Al-Ghamdi MA, et al. COVID-19: Prospective challenges and potential vaccines. Altern Ther Health Med 2020.
22. Oyston P, Robinson K. The current challenges for vaccine development. J Med Microbiol 2012;61(7): 889–894.
23. Middleton JR. Staphylococcus aureus antigens and challenges in vaccine development. Expert Rev Vaccines 2008;7(6):805–815.
24. Bassetti, M.; Vena, A.; Giacobbe, D.R. The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. Eur. J. Clin. Investig. 2020, 50, e13209. [CrossRef].
25. Jean, S.-S.; Lee, P.-I.; Hsueh, P.-R. Treatment options for COVID-19: The reality and challenges. J. Microbiol. Immunol. Infect. 2020, 53, 436–443. [CrossRef]
26. Sah, R.; Shrestha, S.; Mehta, R.; Sah, S.K.; Raaban, A.R.; Dharma, K.; RodriguezMorales, A.J. AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges and solutions in Nepal. Travel Med. Infect. Dis. 2021, 40, 101989. [CrossRef] [PubMed].
27. Sharma, O.; Sultan, A.A.; Ding, H.; Triggle, C.R. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front. Immunol. 2020, 11, 2413. [CrossRef] [PubMed].
28. Glass RI, Parashar U, Patel M, Gentsch J, Jiang B (2013) Rotavirus vaccines: Successes and challenges. J Infect 68 (Suppl 1): S9-S18.
29. Bachmann MF, Jennings GT (2011) Therapeutic vaccines for chronic diseases: successes and technical challenges. Phil Trans R Soc B 366(1579): 2815-2822.
30. Pronker ES, Weenen TC, Commandeur H, Claassen EHJHM, Osterhaus ADME. Risk in vaccine research and development quantified. PLoS One. 2013;8(3):e57755.
doi:10.1371/journal. pone.0057755.
31. Graham BS.Rapid COVID-19 vaccine development. Science,2020;368(6494):945–46. doi:10.1126/science.abb8923.
32. Bachmann MF, Jennings GT (2011) Therapeutic vaccines for chronic diseases: successes and technical challenges. Phil Trans R Soc B 366(1579): 2815-2822.
33. Glass RI, Parashar U, Patel M, Gentsch J, Jiang B (2013) Rotavirus vaccines: Successes and challenges. J Infect 68 (Suppl 1): S9-S18.
34. Arora NK, Lal AA, Hombach JM, Santos JI, Bhutta ZA, et al. (2013) The need for targeted implementation research to improve coverage of basic vaccines and introduction of new vaccines. Vaccine 31(S2): 129-136.
35. Plotkin SA, Mahmoud AA, Farrar J. Establishing a global vaccine development fund. N Engl J Med. 2015;373:297-300.